Poster Session B

Poster Session B
Friday, May 11
4:30 p.m.-7:00 p.m.

In alphabetical order, not board assignment order

• A genome-scale RNA interference screen for resistance mechanisms to BRAF inhibition in melanoma, Steven Whittaker, The Broad Institute, Cambridge, MA
• A novel MEK2 mutation and BRAF amplification associated with resistance to BRAF/MEK inhibitors in melanoma, Jessie Villanueva, The Wistar Institute, Philadelphia, PA
• Activated MAPK Pathway Mediates Resistance to Romidepsin via Bim Degradation in Romidepsin-Selected HuT 78 Cells, Arup Chakraborty, National Institute of Health, Bethesda, MD
• Activation of Wnt/β-Catenin Signaling Enhances TRAIL Dependent Apoptosis in Human Melanoma, Zachary Zimmerman, University of Washington, Seattle, WA
• Alisertib (MLN8237), an Aurora Kinase A inhibitor, enhances Docetaxel-induced cell death in Upper Gastrointestinal Adenocarcinoma cells, Wael El-Rifai, Vanderbilt University Medical Center, Nashville, TN
• Alternate receptor tyrosine kinases provide protection from FGFR inhibition in HNSCC cells as identified by genome-wide shRNA screening, Katherine Singleton, University of Colorado Anschutz Medical Center, Aurora, CO
• Angiotensin IV-Related Hepatocyte Growth Factor Antagonists act as Anti-Angiogenic Anti-Cancer Agents, Leen Kawas, Washington State University, Pullman, WA
• Annexin V inhibits local but not systemic murine fibrosarcoma growth by blocking phosphatidylserine, Chaobo Yin, University of Iowa, Iowa City, IA
• BH3-only protein silencing contributes to acquired resistance to PLX4720 in human melanoma, Yongping Shao, Thomas Jefferson University, Philadelphia, PA
• Bortezomib induces G2-M arrest through ROS-inducible phosphorylation of ATM-CHK1 in human colon cancer cells, Hong Seung-Woo, Asan Medical center, Seoul, Korea (Rep.)
• Cancer cell spheroids as a model to study sequential chemotherapy protocols, Federico Perche, Northeastern University Center for Pharmaceutical Biotechnology and Nanomedicine, Boston, MA
• Colorectal cancer HCT116 cells resistant toward a novel Aurora kinase inhibitor CYC116: Molecular hallmarks of drug resistance and pharmacologic interventions restoring the drug sensitivity, Madhusudhan Reddy Kollareddy, Institute of Molecular and Translational Medicine, Olomouc, Moravia, Czech Republic
• Colorectal Cancer in the Setting of Inflammatory Bowel Disease: Role of Hemoglobin, Amosy M'Koma, Meharry Medical College School of Medicine, Nashville, TN
• Combination treatments of SCLC with ABT-263 and Immunotoxins produces synergistic killing of ABT-263-resistant cells, Abid Mattoo, National Cancer Institute, Bethesda, MD
• CpG-siRNA conjugates: Overcoming cancer immunoresistance, Sergey Nechaev, Irell and Manella Graduate School of Biological Sciences, Duarte, CA
• De novo and acquired resistance to first-line standard therapy in colorectal cancer: from cell lines to metastatic tumors, Therese Gagnon-Kugler, Quebec Clinical Research Organization in Cancer, Montreal, QC, Canada
• Design and synthesis of GADD45β agonists for sorafenib-resistance hepatocellular carcinoma cells, Chung-Wai Shiau, Institute of Biopharmaceutical Sciences, National Yang-Ming University, Taipei, Taiwan
• Development of a Novel Strategy to Overcome Drug Resistance by Targeting ATP Citrate Lyase and de novo Lipogenesis in Colorectal Cancer Cells, Yunfei Zhou
• Downregulation of vimentin confers resistance to the microtubule stabilizing agents peloruside A and laulimalide in 1A9 human ovarian carcinoma cells, Arun Kanakkanthara, Victoria University of Wellington, Wellington, New Zealand
• Drug-Diagnostic co-development to target FLT3-ITD mutations in chemo-resistant acute myeloid leukemia cells, Tsai Jane SC, Industrial Technology Research Institute, Hsinchu, Taiwan
• Dual mTORC1/mTORC2 inhibition limits tumor growth, VEGF production and vascular regrowth, Sharon Barr, OSI Pharmaceuticals, a subsidiary of Astellas Oncology, Farmingdale, NY
• Everolimus inhibits invasion and angiogenesis in a KRAS-mutated mesenchymal-differentiated colorectal cancer xenografts, Annemilai Tijeras-Raballand, AAREC Filia Research, Boulogne-Billancourt, France
• FOXD3 enhances expression of ERBB3 and promotes resistance to vemurafenib, Kevin Basile, Thomas Jefferson University, Philadelphia, PA
• Galpha12 signaling through stimulation of HB-EGF secretion abolishes lung cancer cell apoptosis, MiRan Seo, SIRIC, Yonsei University Hospital, Seoul, Korea (Rep.)
• Heat Shock Protein 27 (HSP27, HSPB1) is up-regulated by MET kinase inhibition and limits the effectiveness of inhibitors, Daniele Musiani, Institute for Cancer Research and Treatment, IRCC, Turin, Italy
• Heterologous Expression of Serine Palmitoyltransferase-1 Alters Chemosensitivity and Multidrug Resistance Profile of Human Cancer Cells of Different Tissue Origins, Tokunbo Yerokun, Spelman College, Atlanta, GA
• HuR cytoplasmic translocation and doxorubicin: how phosphorylation is involved in chemoresistance, Elisa Latorre, University of Trento - Centre for Integrative Biology - CIBIO, Trento, Italy
• Identification of a novel ALK inhibitor active against Crizotinib-allele resistant mutants, Jean-paul Nicolas, Sanofi Oncology, Vitry Sur Seine, France
• Identifying mechanisms of drug resistance to MAPK pathway inhibition via genome-scale rescue screens, Cory Johannessen, The Broad Institute of MIT and Harvard, Cambridge, MA
• Impact of Lipid-Substitution on Assembly and Delivery of siRNA by Cationic Polymers, Hamidreza Montazeri Aliabadi, University of Alberta, Edmonton, AB, Canada
• Increased CXCR4 expression and its nuclear localization are associated with invasion in sorafenib and sunitinib-tolerant hepatocarcinoma models, Armand de Gramont, AAREC Filia Research, Boulogne-Billancourt, France
• Inherent resistance to BRAF inhibitors in BRAFV600E colorectal tumors is driven by ligand-dependent activation of the EGFR pathway, Shiva Malek, Genentech, Inc., South San Francisco, CA
• Insensitivity to RAF inhibition by vemurafenib in BRAF mutant colorectal cancer by EGFR-mediated reactivation of MAPK signaling, Ryan Corcoran, Massachusetts General Hospital Cancer Center, Boston, MA
• Insights into the role of Epithelial to Mesenchymal transition (EMT) as an important mechanism of drug-resistance to molecular targeted therapies, Stuart Thomson, OSI Pharmaceuticals LLC, Farmingdale, NY
• Mechanisms of multidrug resistance in AMLs and selective targeting via small molecules, Chengguo Xing, University of Minnesota, Minneapolis, MN
• Mechanisms of resistance of BRAF fusions to first generation selective BRAF inhibitors, Angela Sievert, The Children's Hospital of Philadelphia, Philadelphia, PA
• MET gene copy number related to radiation treatment response and prognosis in breast cancer, Cynthia Veenstra, Linköping University, Linköping, Sweden
• Met-Dependent Positive and Negative Signaling Cascades in Gastric Cancer Cells, Andrea Lai
• MicroRNAs in cancer drug resistance and sensitivity, Jian Zhu, OmicsHealth, Morris Plains, NJ
• Mitochondrial uncoupling protein 2 regulates the effects of paclitaxel on Stat3 activation and cellular survival in lung cancer cells, Wen-Pin Su, National Cheng Kung University Hospital, Tainan, Taiwan
• Modeling BRAF inhibitor resistance in genetically engineered mouse models of melanoma, Lawrence Kwong, University of Texas M.D. Anderson Cancer Center, Houston, TX
• Monitoring kinome response to EGFR inhibition in triple negative breast cancer, Martin Whittle, University of North Carolina, Chapel Hill, NC
• Multiple genomic aberrations in BCR-ABL inhibitor-resistant cells lead to sensitivity towards MEK inhibition, Yibing Yan, Genentech, Inc., South San Francisco, CA
• Overcoming Acquired Resistance in Philadelphia-Positive (Ph+) Leukemia, Jamal Mahajna, Migal, Kiryat Shmona, Israel
• Overcoming drug resistant cancer by hyaluronic acid based nanogel formulated with anticancer drugs, Xin Wei, University of Nebraska Medical Center, Omaha, NE
• Overcoming resistance to B-Raf targeting agents using LPD nanotechnology, Chin-Ying Chung, Pennsylvania State University College of Medicine, Hershey, PA
• Paracrine interactions through CXCL1/2 chemokines promote breast cancer metastasis and chemoresistance, Swarnali Acharyya
• PEGPH20 depletion of pericellular hyaluronan sensitizes high hyaluronan-producing tumor cells in antibody-dependent cell-mediated cytotoxicity, Netai Singha, Halozyme Therapeutics, San Diego, CA
• Per oral nanogel conjugates of activated nucleoside analogs are effective in the treatment of drug-resistant tumors, Thulani Senanayake, University of Nebraska Medical Center, Omaha, NE
• Picropodophyllin (PPP) increases glucose metabolism and lactate production in paediatric glioblastoma cells, Anne-Christine Wong Te Fong, Institute of Cancer Research, Sutton, Surrey England
• Proteasome inhibitor MG132 induces NAG-1 expression through activation of p38 MAPK pathway, Sachie Shimizu, National Institute of Environmental Health Sciences, Research Triangle Park, NC
• PTEN modulates sensitivity to a novel ERK inhibitor in BRAFV600E-mutant melanomas, Clemens Krepler, The Wistar Institute, Philadelphia, PA
• PTTG1 expression predicts sensitivity to the Src inhibitor Saracatinib in ovarian cancer cell lines, Ichiro Nakachi, University of Colorado, Aurora, CO
• Re-activation of protein phosphatase 2A as a multi-target strategy for combating chemotherapy resistance of common cancer types, Jukka Westermarck, University of Turku, Turku, Finland
• Re-expression of miR-200 by natural agents regulates the expression of PTEN and MT1-MMP in pancreatic cancer, Shadan Ali, Wayne State University, Detroit, MI
• Reprogramming of the cancer kinome in response to targeted kinase inhibition, James Duncan, University of North Carolina, Chapel Hill, NC
• Resistance to B-RAF inhibitor is mediated by reactivation of MAPK pathway by FGFR3/Ras signaling in B-RAF V600E mutant melanoma, Vipin Yadav, Eli Lilly and Company, Indianapolis, IN
• Role of inverted Alu repeats in triggering TMPRSS2-ERG fusions in prostate cancer following irradiation, Sheetal Singh, VA Northern California Health Care System, Sacramento, CA
• Sensitization of Hepatocellular Carcinoma Cells to TRAIL by a Novel Aκt/NF-kappaB Signaling Inhibitor, Hany Omar, Beni-Suef University, Beni-Suef, Egypt, Arab Rep.
• Supplementation of dietary fish oil induces apoptosis through activation of PPARγ and involves inhibition of angiogenesis in colon cancer, Shevali Kansal, Panjab University, Chandigarh, Chandigarh India
• Targeting tumor-propagating cells in medulloblastoma through inhibition of G2/M cell cycle regulators, Shirley Markant, Sanford-Burnham Medical Research Institute, La Jolla, CA
• TGF-β2 induction in head and neck squamous cell carcinoma cell lines upon treatment with tyrosine kinase inhibitors as a mechanism of acquired resistance, Emily Kleczko, University of Colorado Anschutz Medical Campus, Aurora, CO
• The ATP-competitive mammalian target of rapamycin (mTOR) inhibitors suppress proliferation and induce apoptosis in the acquired rapamycin resistant breast cancer cells, Wu Tzung-Ju, University of Medicine and Dentistry of NJ, Piscataway, NJ
• The Effects of PI3K/Akt/mTOR Pathway Inhibitors on a Panel of Non Small Cell Lung Cancer (NSCLC) Cell Lines, Susan Heavey, St. James Hospital, Trinity College, Dublin, Ireland
• The HSP90 inhibitor, AT13387, is effective against multiple mechanisms of kinase inhibitor resistance, Nicola Wallis, Astex Pharmaceuticals, Cambridge, England
• The pan-BCR-ABL inhibitor ponatinib inhibits viability of gatekeeper mutant BCR-ABL^T315I cells with greater potency than a nilotinib/MEK inhibitor combination, Alexa Schrock, ARIAD Pharmaceuticals, Cambridge, MA
• Thymoquinone induces-cell cycle non-specific-cell death in cisplatin-resistant ovarian cancer cell through up-regulation of PTEN expression, El-Shaimaa Arafa
• Widespread potential for growth factor-driven resistance to anti-cancer kinase inhibitors, Timothy Wilson, Genentech, Inc., South San Francisco, CA